We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+25.06%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.55B
AUM Growth
+$50.7M
(+3.4%)
Cap. Flow
-$236M
Cap. Flow
% of AUM
-15.23%
Top 10 Holdings %
Top 10 Hldgs %
80.86%
Holding
37
New
7
Increased
10
Reduced
8
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$94.8M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$56M |
| 3 |
Vaxcyte
PCVX
|
+$28.4M |
| 4 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
+$14.6M |
| 5 |
AKUS
Akouos Inc
AKUS
|
+$10.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$401M |
| 2 |
Cable One
CABO
|
+$31M |
| 3 |
Akebia Therapeutics
AKBA
|
+$14.5M |
| 4 |
Apple
AAPL
|
+$9.11M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$7.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.51% |
| 2 | Technology | 8.91% |
| 3 | Communication Services | 6.56% |
| 4 | Financials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Milestone Pharmaceuticals
MIST
$152M
| $7.87M | 0.51% |
2,080,585
| – | – |
|
|
XENT
27
DELISTED
Intersect ENT, Inc
XENT
| $7.56M | 0.49% |
558,515
+187,920
| +51% | +$2.19M |
|
28
Inspire Medical Systems
INSP
$1.74B
| $6.92M | 0.45% |
79,536
-75,086
| -49% | -$5.77M |
|
|
ETTX
29
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
| $6.46M | 0.42% |
2,181,843
| – | – |
|
|
BHVN
30
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.18M | 0.4% |
84,600
+30,500
| +56% | +$1.62M |
|
|
SILK
31
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $6.09M | 0.39% |
145,428
-40,614
| -22% | -$1.56M |
|
32
Crinetics Pharmaceuticals
CRNX
$8.92B
| $3.76M | 0.24% |
214,453
+50,000
| +30% | +$852K |
|
|
NARI
33
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $3.66M | 0.24% |
+75,500
| New | +$3.61M |
|
|
VRNA
34
DELISTED
Verona Pharma
VRNA
| $3.47M | 0.22% |
740,740
| – | – |
|
35
Neuronetics
STIM
$166M
| $992K | 0.06% |
514,190
-388,682
| -43% | -$797K |
|
|
MYOK
36
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – |
-151,816
| Closed | -$7.12M |
|
Similar funds
MP
FLII
IC
IA
HTHT
BCP
SPC
SC
Novo Holdings A/S's Q2 2020 Portfolio in Review
As of Q2 2020, Novo Holdings A/S held 37 positions worth $1.55B, up 3.4% from $1.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.
Novo Holdings A/S withdrew a net $236M in Q2 2020, closing 2 positions and reducing 8 holdings. Its most notable exit was MyoKardia, Inc. Common Stock, an estimated $7.12M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.
Against the trend, Novo Holdings A/S opened a new position in Medtronic worth $90.6M.
- Novo Holdings A/S's largest Q2 2020 buy was Medtronic: 988,136 shares worth $90.6M.
- Novo Holdings A/S added most to Constellation Pharmaceuticals, Inc. in Q2 2020, an estimated $9.68M increase.
- Novo Holdings A/S's biggest Q2 2020 reduction was Vanguard Morningstar Total Stock Market ETF, cutting an estimated $401M.
- Novo Holdings A/S fully exited MyoKardia, Inc. Common Stock in Q2 2020, selling an estimated $7.12M.
- Novo Holdings A/S's ten largest holdings make up 81% of its $1.55B portfolio in Q2 2020.
- Novo Holdings A/S opened 7 new positions and closed 2 in Q2 2020.
- Novo Holdings A/S's portfolio value rose 3.4% quarter-over-quarter to $1.55B.
Based on Novo Holdings A/S's 13F filing for Q2 2020, filed 14 Aug 2020.